Allogeneic bone marrow transplantation for advanced Waldenstrom’s macroglobulinemia

Abstract

Waldenstrom's disease is a lymphoproliferative disorder that is typically treated with plasmapheresis and/or alkylating agents. In young patients, other lymphoproliferative disorders have been treated with allogeneic transplantation. Two patients with aggressive Waldenstrom's disease, who progressed in spite of multi-agent chemotherapy and autologous stem cell transplantation, in one case, underwent allogeneic transplantation from their HLA-identical donors. Both remain alive with event-free survivals of more than 3, and more than 9 years, respectively. Allogeneic transplantation should be considered for young patients with Waldenstrom's disease.

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

“…3,4 Allogeneic stem cell transplantation may improve tumor response due to graft-versus-tumor effect. [5][6][7][8][9][10][11] We have previously obtained encouraging results with allogeneic stem cell transplantation in a series of 10 patients. 4 Here we report longer follow-up of these 10 patients along with data on 15 additional cases.…”

Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia

“…[1][2][3] However, it is still controversial whether this treatment strategy could be as efficient as with most low grade lymphomas. Although a graftversus-tumor effect associated with allogeneic bone marrow transplantation could provide benefit, 4 most patients with this disorder are too old to tolerate the high-dose chemo-radiotherapy associated with the conventional transplantation procedures.…”

Waldenström macroglobulinemia: A review of therapy

“…Two patients were reported who had not responded to prior therapy and underwent human leukocyte antigen sibling-identical allogeneic transplantation. Both are reported to be alive and disease free at 3 and 9 years [79]. At the M.D.…”